Joshua Mason

Company: Mirati Therapeutics

Job title: Director - Medical Affairs Strategy

Seminars:

Targeting Tumors with KRAS G12C Mutations with Adagrasib (MRTX849): Current Status & Future Questions 10:00 am

History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C Clinical progress of KRAS G12C inhibitors (eg, adagrasib) in the clinic Future questions and directions for targeting KRAS G12CRead more

day: Day One